Sales down 16% y-o-y as EEs remained flat q-o-q, 7% below us We push forward recovery a bit, but wil...
Redeye comments on BioInvent’s first quarter in 2025.
Det var en väntat stark och stabil rapport som Eastnine kom med för det första kvartalet.
Redeye reiterates its base case following the company’s Q1 report.
Visserligen föll Aixias nettoomsättning till 85,9 (205,6) mkr, men fjolårssiffran innehåller jätteor...
Redeye shares its initial take on Modelon’s Q1 2025 results, with ARR slightly below expectations wh...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 29 april 2025 att Bolaget har ingått ett ex...
Redeye comments on Medivir's Q1 report, during which the main events were the completion of the phas...
Redeye comments on Evolution’s Q1-results which were somewhat weaker than expected, driven by soft r...
Redeye provides an update following SSH's Q1 2025 were sales increased by 8% y/y to EUR5.
Redeye updates its view on M.O.B.A. Network following the Q1 2025 report.
Redeye updates its estimates and valuation for Tradedoubler following the Q1 2025 report.
Taaleri's Q1 headline figures missed our and LSEG consensus' estimates, but the miss can be explaine...
Order momentum from Q4 continues, up 18% y-o-y, de-risking '25e Stronger margin in both segments, bu...
Q1: +29% org. sales growth, SEK 9m adj. EBITA improvement '25e-'27e adj.
